| Evolution and impact of subclonal mutations in chronic lymphocytic leukemia DA Landau, SL Carter, P Stojanov, A McKenna, K Stevenson, ... Cell 152 (4), 714-726, 2013 | 1653 | 2013 |
| SF3B1 and other novel cancer genes in chronic lymphocytic leukemia L Wang, MS Lawrence, Y Wan, P Stojanov, C Sougnez, K Stevenson, ... New England Journal of Medicine 365 (26), 2497-2506, 2011 | 1410 | 2011 |
| Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia DA Landau, K Clement, MJ Ziller, P Boyle, J Fan, H Gu, K Stevenson, ... Cancer cell 26 (6), 813-825, 2014 | 387 | 2014 |
| Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity BL Lampson, SN Kasar, TR Matos, EA Morgan, L Rassenti, MS Davids, ... Blood, The Journal of the American Society of Hematology 128 (2), 195-203, 2016 | 331 | 2016 |
| Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution S Kasar, J Kim, R Improgo, G Tiao, P Polak, N Haradhvala, MS Lawrence, ... Nature communications 6 (1), 8866, 2015 | 286 | 2015 |
| Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies R Guièze, VM Liu, D Rosebrock, AA Jourdain, M Hernández-Sánchez, ... Cancer cell 36 (4), 369-384. e13, 2019 | 281 | 2019 |
| Transcriptomic characterization of SF3B1 mutation reveals its pleiotropic effects in chronic lymphocytic leukemia L Wang, AN Brooks, J Fan, Y Wan, R Gambe, S Li, S Hergert, S Yin, ... Cancer cell 30 (5), 750-763, 2016 | 223 | 2016 |
| Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia J Deng, E Isik, SM Fernandes, JR Brown, A Letai, MS Davids Leukemia 31 (10), 2075-2084, 2017 | 196 | 2017 |
| LNA-mediated anti–miR-155 silencing in low-grade B-cell lymphomas Y Zhang, AM Roccaro, C Rombaoa, L Flores, S Obad, SM Fernandes, ... Blood, The Journal of the American Society of Hematology 120 (8), 1678-1686, 2012 | 183 | 2012 |
| Measurement of θ 13 in Double Chooz using neutron captures on hydrogen with novel background rejection techniques Y Abe, S Appel, T Abrahao, H Almazan, C Alt, JC dos Anjos, JC Barriere, ... Journal of High Energy Physics 2016 (1), 1-29, 2016 | 147 | 2016 |
| Growth dynamics in naturally progressing chronic lymphocytic leukaemia M Gruber, I Bozic, I Leshchiner, D Livitz, K Stevenson, L Rassenti, ... Nature 570 (7762), 474-479, 2019 | 126 | 2019 |
| Enhancer architecture and essential core regulatory circuitry of chronic lymphocytic leukemia CJ Ott, AJ Federation, LS Schwartz, S Kasar, JL Klitgaard, R Lenci, Q Li, ... Cancer cell 34 (6), 982-995. e7, 2018 | 124 | 2018 |
| Survival of Del17p CLL depends on genomic complexity and somatic mutation L Yu, HT Kim, SN Kasar, P Benien, W Du, K Hoang, A Aw, B Tesar, ... Clinical Cancer Research 23 (3), 735-745, 2017 | 111 | 2017 |
| Integrative Genomic Analysis Implicates Gain of PIK3CA at 3q26 and MYC at 8q24 in Chronic Lymphocytic Leukemia JR Brown, M Hanna, B Tesar, L Werner, N Pochet, JM Asara, YE Wang, ... Clinical Cancer Research 18 (14), 3791-3802, 2012 | 110 | 2012 |
| Background-independent measurement of θ13 in Double Chooz Y Abe, JC Dos Anjos, JC Barriere, E Baussan, I Bekman, M Bergevin, ... Physics Letters B 735, 51-56, 2014 | 99 | 2014 |
| C1 inhibitor-mediated protection from sepsis D Liu, F Lu, G Qin, SM Fernandes, J Li, AE Davis The Journal of Immunology 179 (6), 3966-3972, 2007 | 98 | 2007 |
| Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL MV Haselager, K Kielbassa, J Ter Burg, DJC Bax, SM Fernandes, J Borst, ... Blood, The Journal of the American Society of Hematology 136 (25), 2918-2926, 2020 | 91 | 2020 |
| Molecular map of chronic lymphocytic leukemia and its impact on outcome BA Knisbacher, Z Lin, CK Hahn, F Nadeu, M Duran-Ferrer, KE Stevenson, ... Nature genetics 54 (11), 1664-1674, 2022 | 90 | 2022 |
| Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia R Thijssen, J Ter Burg, B Garrick, GGW van Bochove, JR Brown, ... Blood, The Journal of the American Society of Hematology 128 (4), 574-583, 2016 | 86 | 2016 |
| Mechanism of EBV inducing anti-tumour immunity and its therapeutic use IK Choi, Z Wang, Q Ke, M Hong, DW Paul Jr, SM Fernandes, Z Hu, ... Nature 590 (7844), 157-162, 2021 | 62 | 2021 |
Jennifer R BrownProfessor of Medicine, Harvard Medical School在 dfci.harvard.edu 的电子邮件经过验证
